Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KK6L
|
|||
| Drug Name |
PMID26560530-Compound-13
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Apotex Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N6O6S2
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)NCCCCCCN(CC(=O)O)C2=NSC3=NC=CN23
|
|||
| InChI |
1S/C18H22N6O6S2/c25-16(26)13-22(17-21-31-18-19-10-12-23(17)18)11-6-2-1-5-9-20-32(29,30)15-8-4-3-7-14(15)24(27)28/h3-4,7-8,10,12,20H,1-2,5-6,9,11,13H2,(H,25,26)
|
|||
| InChIKey |
NCXBWLQKBKSTHD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor XIIIA (F13A1) | Target Info | Inhibitor | [1] |
| Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Coagulation factor XIIIA (F13A1) | Target's Patent Info | [1] | |
| Tissue transglutaminase (TG2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Huntington's disease | |||
| Complement and coagulation cascades | ||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.